Martin O Leach

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging
    M O Leach
    Cancer Research UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2, 5PT, UK
    Eur Radiol 22:1451-64. 2012
  2. ncbi Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study
    Deborah J Thompson
    Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 11:R80. 2009
  3. ncbi Image fusion for dynamic contrast enhanced magnetic resonance imaging
    Thorsten Twellmann
    Applied Neuroinformatics Group, Faculty of Technology, University of Bielefeld, Germany
    Biomed Eng Online 3:35. 2004
  4. ncbi The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
    M O Leach
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 92:1599-610. 2005
  5. ncbi Breast cancer screening in women at high risk using MRI
    Martin O Leach
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    NMR Biomed 22:17-27. 2009
  6. ncbi Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
    M O Leach
    MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Lancet 365:1769-78. 2005
  7. ncbi Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Res 72:990-1000. 2012
  8. ncbi Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor
    Keiko Miyazaki
    CRUK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Eur Radiol 18:1414-21. 2008
  9. ncbi The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy
    Nada M S Al-Saffar
    Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Res 70:5507-17. 2010
  10. ncbi Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response
    Keiko Miyazaki
    Institute of Cancer Research, Cancer Research UK and EPSRC Cancer Imaging Centre, Sutton, Surrey SM2 5NG, England
    Radiology 263:139-48. 2012

Collaborators

Detail Information

Publications124 found, 100 shown here

  1. ncbi Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging
    M O Leach
    Cancer Research UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2, 5PT, UK
    Eur Radiol 22:1451-64. 2012
    ....
  2. ncbi Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study
    Deborah J Thompson
    Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 11:R80. 2009
    ....
  3. ncbi Image fusion for dynamic contrast enhanced magnetic resonance imaging
    Thorsten Twellmann
    Applied Neuroinformatics Group, Faculty of Technology, University of Bielefeld, Germany
    Biomed Eng Online 3:35. 2004
    ..Even though these techniques provide new information, integrating and evaluating the much wider range of information is a challenging task for the human observer. This task may be assisted with the use of image fusion algorithms...
  4. ncbi The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
    M O Leach
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 92:1599-610. 2005
    ..This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used...
  5. ncbi Breast cancer screening in women at high risk using MRI
    Martin O Leach
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    NMR Biomed 22:17-27. 2009
    ..Recommendations for screening women at high risk of breast cancer published by the American Cancer Society and from the National Institute for Health and Clinical Excellence (NICE) in the UK are summarised...
  6. ncbi Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
    M O Leach
    MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Lancet 365:1769-78. 2005
    ..Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening...
  7. ncbi Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Res 72:990-1000. 2012
    ..Together, our findings provide mechanistic insights into the impact of HDAC inhibition on cancer cell metabolism and highlight PC as a candidate noninvasive imaging biomarker for monitoring the action of HDAC inhibitors...
  8. ncbi Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor
    Keiko Miyazaki
    CRUK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Eur Radiol 18:1414-21. 2008
    ..05). This pilot study demonstrates that HPI determined using quantified Gd-DTPA concentration is reproducible and may be useful for monitoring antiangiogenic treatment response of hepatic metastases...
  9. ncbi The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy
    Nada M S Al-Saffar
    Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Res 70:5507-17. 2010
    ..Our results show that monitoring the effects of PI3K inhibitors by MRS may provide a noninvasive PD biomarker for PI3K inhibition and potentially of tumor response during early-stage clinical trials with PI3K inhibitors...
  10. ncbi Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response
    Keiko Miyazaki
    Institute of Cancer Research, Cancer Research UK and EPSRC Cancer Imaging Centre, Sutton, Surrey SM2 5NG, England
    Radiology 263:139-48. 2012
    ....
  11. ncbi Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls
    Dow Mu Koh
    Department of Radiology, Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM25PT, UK
    AJR Am J Roentgenol 199:252-62. 2012
    ..Meticulous technique and knowledge of potential interpretive pitfalls will help to avoid mistakes and establish this modality in radiologic practice...
  12. ncbi Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Centre for Cancer Imaging, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
    Cell Cycle 10:2883-93. 2011
    ..Finally, the translation of these metabolic measurements from pre-clinical models to patients will be discussed...
  13. ncbi Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models
    Nada M S Al-Saffar
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Res 66:427-34. 2006
    ..The decrease in phosphocholine, total choline, and phosphomonoesters may have potential as noninvasive pharmacodynamic biomarkers for determining tumor response following treatment with choline kinase inhibitors...
  14. ncbi Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR
    Cristina Gabellieri
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    NMR Biomed 22:456-61. 2009
    ....
  15. ncbi Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry
    Geoffrey S Payne
    Cancer Research UK Clinical Magnetic Resonance Research Group, Royal Marsden NHS Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey, SM25PT, UK
    Cancer Chemother Pharmacol 56:409-14. 2005
    ..In particular, the distribution of ifosfamide and its metabolites into bile may be related to oxazophosphorine-related cholecystitis reported in patients...
  16. ncbi Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Mol Cancer Ther 5:187-96. 2006
    ..05), whereas the levels of the remaining metabolites did not change significantly. Our results indicate that PI3K inhibition in human breast cancer cells by LY294002 and wortmannin is associated with a decrease in phosphocholine levels...
  17. ncbi Hyperpolarized (13)C magnetic resonance detection of carboxypeptidase G2 activity
    Yann Jamin
    CRUK and EPSRC Cancer Imaging Centre, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Magn Reson Med 62:1300-4. 2009
    ..We discuss the feasibility of translating these experiments to generate metabolic images of CPG2 activity in vivo...
  18. ncbi Optimizing functional parameter accuracy for breath-hold DCE-MRI of liver tumours
    Matthew R Orton
    Cancer Research UK Clinical MR Research Group, Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK
    Phys Med Biol 54:2197-215. 2009
    ..The simulation results show that the protocol consisting of two images per breath-hold is to be preferred as it requires identical patient co-operation, but provides parameter estimates that have superior accuracy and precision...
  19. ncbi Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI
    Matthew R Orton
    Cancer Research UK Clinical MR Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Phys Med Biol 53:1225-39. 2008
    ..These results were obtained from five example data sets, one of which was examined in more detail to compare the estimates obtained using the different models, and with literature values...
  20. ncbi Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivoF magnetic resonance spectroscopy
    Geoffrey S Payne
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Br J Clin Pharmacol 59:244-8. 2005
    ..To measure hepatic concentrations of the fluorine-containing antimicrobial, sitafloxacin, using in vivo(19)F magnetic resonance spectroscopy (MRS)...
  21. ncbi Therapeutic target metabolism observed using hyperpolarized 15N choline
    Cristina Gabellieri
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Downs Road Sutton, Surrey, SM2 5PT, United Kingdom
    J Am Chem Soc 130:4598-9. 2008
    ..4 min, providing a method to observe the action of choline kinase, an important target for novel cancer therapeutics...
  22. ncbi Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies
    Paul Workman
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
    J Natl Cancer Inst 98:580-98. 2006
    ..Development, validation, and implementation of minimally invasive PK/PD methods are encouraged...
  23. ncbi Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity
    Christina Messiou
    Cancer Research UK and EPSRC Imaging Centre and Drug Development Unit of Section of Medicine, Institute of Cancer Research and Royal Marsden Hospital, MRI Unit, Downs Road, Sutton, Surrey SM2 5PT, England Department of Radiology, Royal Marsden NHS Foundation Trust, Sutton, Surrey, England
    Radiology 265:426-36. 2012
    ..RSNA, 2012 Clinical trial registration no. NCT00748891 Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12112565/-/DC1...
  24. ncbi Noninvasive detection of carboxypeptidase G2 activity in vivo
    Yann Jamin
    Cancer Research UK and EPRSC Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    NMR Biomed 24:343-50. 2011
    ..The addition of in vivo reporter probes, such as 3,5-DFBGlu, to the armamentarium of prodrugs cleaved by CPG2 affords new applications for CPG2 as a gene reporter of transgene expression...
  25. ncbi Comparison of polarization transfer sequences for enhancement of signals in clinical 31P MRS studies
    Laura Mancini
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Magn Reson Med 50:578-88. 2003
    ..Among the PT methods, INEPT gave the higher signal enhancement. However, T(2) losses during the long echo times (TEs) required by the weak coupling limited the resulting signals from PC...
  26. ncbi Localized COSY and DQF-COSY 1H-MRS sequences for investigating human tibial bone marrow in vivo and initial application to patients with acute leukemia
    Andrew P Prescot
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Sutton, Surrey, UK
    J Magn Reson Imaging 22:541-8. 2005
    ..CONCLUSIONS: No significant differences were observed in the spectra obtained from bone marrow using the 2D 1H-MRS sequences. A novel unsaturated lipid proton index was developed...
  27. ncbi Conformational exchange in pimonidazole--a hypoxia marker
    Cristina Gabellieri
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom, UK
    Magn Reson Chem 45:621-3. 2007
    ..By a combination of 1H, 13C, two-dimensional 1H-1H EXchange SpectroscopY (EXSY) and spectral simulation, we unambiguously attribute the conformational exchange process to flipping of the six-membered heterocyclic ring...
  28. ncbi Bayesian estimation of pharmacokinetic parameters for DCE-MRI with a robust treatment of enhancement onset time
    Matthew R Orton
    Cancer Research UK Clinical MR Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Phys Med Biol 52:2393-408. 2007
    ..A more detailed method of assessing the uncertainty of the Bayesian approach is described, and the results show that this is a more accurate description of the estimation uncertainty...
  29. ncbi Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Oncotarget 1:185-97. 2010
    ..Our findings provide a basis for using metabolic changes as non-invasive indicators of Hsp90 inhibition and potentially as biomarkers of anticancer activity with Hsp90 drugs in malignant melanoma and possibly in other cancers...
  30. ncbi Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial
    Dow Mu Koh
    Department of Radiology, Royal Marsden Hospital, Downs Road, SM25PT Sutton, UK
    Eur Radiol 19:2728-38. 2009
    ..05). ADC measurements were highly reproducible in a two-centre clinical trial setting and appear promising for evaluating the effects of drugs that target tumour vasculature...
  31. ncbi Preliminary dose response study of a gel dosimeter using 2-Hydroxyethyl Methacrylate (HEMA)
    J V Trapp
    Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Australas Phys Eng Sci Med 28:172-4. 2005
    ..The gel is shown to provide a signal to noise ratio of up to at least 35 and have a linear change in transverse relaxation rate up to 70 Gy when measured with magnetic resonance imaging...
  32. ncbi Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data
    James A d'Arcy
    Cancer Research UK Clinical MR Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, United Kingdom SM2 5PT
    Radiographics 26:621-32. 2006
    ..MRIW is written in IDL, enabling it to be used on a variety of computer systems...
  33. ncbi A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy
    Laura Mancini
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    NMR Biomed 22:561-6. 2009
    ..The MRS conversion half-life (470 min) agreed with that measured by HPLC (500 min). This substrate is, therefore, suitable for evaluating gene delivery and expression prior to administration of the therapeutic agent...
  34. ncbi Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Mol Cancer Ther 8:1305-11. 2009
    ....
  35. ncbi Implementation and evaluation of CSI-localized J cross-polarization for detection of 31P magnetic resonance spectra in vivo
    Laura Mancini
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Magn Reson Med 54:1065-71. 2005
    ..Such enhancement could be used to reduce the measurement times for equivalent signal-to-noise ratios. The JCP sequence is, however, slightly more sensitive than INEPT to RF field inhomogeneities, as predicted from theory...
  36. ncbi Computed diffusion-weighted MR imaging may improve tumor detection
    Matthew D Blackledge
    Cancer Research UK and Engineering and Physical Sciences Research Council Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, England
    Radiology 261:573-81. 2011
    ....
  37. ncbi Investigation of microenvironmental factors influencing the longitudinal relaxation times of drugs and other compounds
    A S K Dzik-Jurasz
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Sutton, Surrey, SM2 5PT
    Magn Reson Imaging 22:973-82. 2004
    ..The relevance of the findings to in vivo studies is discussed...
  38. ncbi In vivo hyperpolarized 129Xe NMR spectroscopy in tumors
    J Wolber
    CRC Clinical Magnetic Resonance Research Group and Physics Department, The Institute of Cancer Research, The Royal Marsden NHS Trust, Button, Surrey, UK
    Magn Reson Med 46:586-91. 2001
    ..These differences are discussed in terms of xenon exchange between the carrier medium and the tissue compartments...
  39. ncbi Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours
    A J Schwarz
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Radiol 75:959-66. 2002
    ..Moreover, the differential changes observed in the tCho region of the spectrum suggest that (1)H MRS could provide an early and sensitive indicator of metabolic response to chemotherapy...
  40. ncbi Polymer gel measurement of dose homogeneity in the breast: comparing MLC intensity modulation with standard wedged delivery
    P A Love
    Joint Department of Physics, The Institute of Cancer Research, The Royal Marsden NHS Trust, Sutton, UK
    Phys Med Biol 48:1065-74. 2003
    ..Gel dose distributions from the multileaf modulation treatment show an improved dose uniformity in comparison to the standard treatment with a decreased volume receiving doses over 105%...
  41. ncbi Informatics in Radiology: Development of a Research PACS for Analysis of Functional Imaging Data in Clinical Research and Clinical Trials
    Simon J Doran
    Cancer Research UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research, 15 Cotswold Rd, Sutton SM2 5NG, England, and The Royal Marsden NHS Foundation Trust, Sutton, England
    Radiographics 32:2135-50. 2012
    ..rsna, 2012...
  42. ncbi Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Cancer Res 65:3356-63. 2005
    ..Thus, phosphocholine has potential as a noninvasive pharmacodynamic marker for monitoring MAPK signaling blockade...
  43. ncbi A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy
    Beatrice M Seddon
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Clin Cancer Res 9:5101-12. 2003
    ..CONCLUSIONS: SR-4554 has plasma pharmacokinetic and toxicity profiles suitable for use as a hypoxia probe. It can be detected in tumors by unlocalized MRS. Additional clinical studies are warranted...
  44. ncbi Reference tissue quantification of DCE-MRI data without a contrast agent calibration
    Simon Walker-Samuel
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK
    Phys Med Biol 52:589-601. 2007
    ..Both of these uncertainties are of the order of those associated with the conversion to Gd-DTPA concentration, according to literature estimates...
  45. ncbi Inversion recovery measurements in the presence of radiation damping and implications for evaluating contrast agents in magnetic resonance
    Thomas R Eykyn
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden Foundation NHS, Downs Road Sutton, Surrey, SM2 5PT, UK
    Phys Med Biol 50:N371-6. 2005
    ....
  46. ncbi A complete distortion correction for MR images: II. Rectification of static-field inhomogeneities by similarity-based profile mapping
    Stefan A Reinsberg
    Cancer Research UK Clinical MR Research Group, Royal Marsden NHS Trust Institute of Cancer Research, Downs Rd, Sutton SM2 5PT, UK
    Phys Med Biol 50:2651-61. 2005
    ..Image quality is preserved to a degree not reported previously...
  47. ncbi Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts
    Yuen Li Chung
    Cancer Research UK, Biomedical Magnetic Resonance Research Group, Department of Basic Medical Sciences, St George s University of London, London, UK
    Neoplasia 10:303-13. 2008
    ..The phosphocholine and phosphomonoester increases may have the potential to act as pharmacodynamic markers for noninvasively monitoring tumor response after treatment with LAQ824 or other HDAC inhibitors...
  48. ncbi Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging
    D M Koh
    Cancer Research UK Magnetic Resonance Clinical Research Group, Institute of Cancer Research, Sutton, UK
    Eur Radiol 16:1898-905. 2006
    ..However, the estimated F was found to be lower in metastases compared to liver (P = 0.03, Mann-Whitney test). Colorectal hepatic metastases were characterised by higher ADC1 and ADC2 values, but lower F values compared to liver...
  49. ncbi Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination
    D M Koh
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Sutton, UK
    Eur Radiol 18:903-10. 2008
    ..There was no difference in the averaged specificity using any of the three image sets (p>0.5). Combination of MnDPDP MR imaging and DWI resulted in the highest diagnostic accuracy and can increase sensitivity without loss in specificity...
  50. ncbi A modified polymer gel for radiotherapy dosimetry: assessment by MRI and MRS
    P S Murphy
    Joint Department of Physics, The Institute of Cancer Research, The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Phys Med Biol 45:3213-23. 2000
    ..MR spectroscopy revealed that the crosslinking co-monomer is consumed more readily than the monomer, which is in agreement with previous compositional studies...
  51. ncbi Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy
    M Beloueche-Babari
    Section of Magnetic Resonance, Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Surrey SM2 5PT, UK
    Br J Cancer 102:1-7. 2010
    ..We describe the MRS-detectable PD biomarkers resulting from the action of targeted therapeutics, and discuss their biological significance and future translation into clinical use...
  52. ncbi Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function
    S Walker-Samuel
    Cancer Research UK Clinical Magnetic Resonance Imaging Research Group, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Phys Med Biol 52:75-89. 2007
    ..This study therefore provides an indirect validation of the methodology...
  53. ncbi Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis
    S Walker-Samuel
    Cancer Research UK Clinical Magnetic Resonance Imaging Research Group, Royal Marsden and NHS Foundation Trust and Institute of Cancer Research, Belmont, Surrey SM2 5PT, UK
    Phys Med Biol 51:3593-602. 2006
    ..Furthermore, it is demonstrated that the range over which IAUGC is taken and the nature of the vascular input function do not significantly affect this relationship...
  54. ncbi Pre-processed image reconstruction applied to breast and brain MR imaging
    A Degenhard
    CRC Clinical MR Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Physiol Meas 22:589-604. 2001
    ..The developed algorithm requires a full Fourier space acquisition of a pre-contrast or baseline image prior to the reconstruction procedure of the time series partial Fourier data...
  55. ncbi The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS)
    M O Leach
    Section of Magnetic Resonance, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    J Exp Clin Cancer Res 21:107-14. 2002
    ..15 cancers have been detected to date, from a total of 1236 screening measurements. This event rate and the tumour grades reported are compared with recent reports from other studies in women at high risk of breast cancer...
  56. ncbi Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T
    A S K Dzik-Jurasz
    CRC Clinical Magnetic Resonance Research Group, Institute of Cancer Research and the Royal Marsden NHS Trust, Surrey, UK
    Magn Reson Med 47:809-11. 2002
    ..Localized proton spectra were acquired at short (20 ms) and long (135 ms) echo times (TEs) using a single-voxel technique. The most commonly detected metabolites were choline and lipid...
  57. ncbi A model to assess SAR for surface coil magnetic resonance spectroscopy measurements
    T Prock
    CRC Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Phys Med Biol 47:1805-17. 2002
    ..A comparative study shows that up to 100% more energy may be applied to surface coils if SAR values are determined for 10 g tissue masses rather than 1 g tissue masses...
  58. ncbi Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells
    N M S Al-Saffar
    Cancer Research UK Clinical Magnetic Resonance Research Group, Royal Marsden NHS Trust, Downs Road, Sutton Surrey SM2 5PT, UK
    Br J Cancer 86:963-70. 2002
    ..This is reflected in an increase in the methylene/methyl ratio which could be detected by magnetic resonance spectroscopy...
  59. ncbi Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI
    J A d'Arcy
    CRC Clinical MR Research Group, Institute of Cancer Research and the Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    NMR Biomed 15:174-83. 2002
    ..It is implemented here as a dual gradient echo sequence providing simultaneous T(1)- and T(2)*-weighted images with a time resolution of 1.1 s...
  60. ncbi Surface-coil polarization transfer for monitoring tissue metabolism in vivo
    G S Payne
    CRC Clinical Magnetic Resonance Research Group, Institute of Cancer Research, The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Magn Reson Med 43:510-6. 2000
    ..Finally, in vivo data are presented from the liver of a normal volunteer in which the signals from the phosphodiester peaks are substantially enhanced...
  61. ncbi Imaging biochemistry: applications to breast cancer
    S M Ronen
    Institute of Cancer Research, Sutton, Surrey, UK
    Breast Cancer Res 3:36-40. 2001
    ..Experiments in model systems aimed at understanding the underlying biochemical processes are presented, as well as data indicating the usefulness of MRS in monitoring the uptake and metabolism of some chemotherapeutic agents...
  62. ncbi Application of magnetic resonance imaging to angiogenesis in breast cancer
    M O Leach
    CRC Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Breast Cancer Res 3:22-7. 2001
    ..These studies show correlation between in vivo dynamic contrast measurements and in vitro histopathology. Dynamic contrast-enhanced MRI is also being applied to assessment of the response of breast tumours to treatment...
  63. ncbi In vivo multiple spin echoes
    A Bifone
    CRC Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Sutton, SM2 5PT, United Kingdom
    J Magn Reson 135:30-6. 1998
    ..The dependence of the signal amplitudes on the experimental parameters is compared with the theory. The sources of contrast for MRI and the perspectives for medical applications are discussed...
  64. ncbi Numerical evaluation of shaped surface coil sensitivity at 63 MHz
    T Prock
    CRC Clinical MR Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Phys Med Biol 46:1753-65. 2001
    ..Simulations are validated experimentally using both B1 and SNR mapping techniques. A comparison between the axial SNR of circular and square coils demonstrated equal SNR distributions of coils with equivalent area at depth...
  65. ncbi SAR and tissue heating with a clinical (31)P MRS protocol using surface coils, adiabatic pulses, and proton-decoupling
    A J Schwarz
    CRC Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
    Magn Reson Med 44:692-700. 2000
    ..The heating rate and maximum temperature in the gel, at positions guided by the simulations, were within guideline values for both extremities and trunk and in reasonable agreement with that predicted...
  66. ncbi The quantitative 19F-imaging of albumin at 1.5 T: a potential in-vivo tool
    A S Dzik-Jurasz
    The CRC Clinical Magnetic Resonance Research Group, SM2 5PT, Sutton, UK
    Magn Reson Imaging 19:839-44. 2001
    ..15). The potentially interfering effect of paramagnetic species on T1 relaxation times was also investigated. Relaxivity data show that albumin concentration measurements should be performed prior to any contrast agent administration...
  67. ncbi Vascular occlusion using focused ultrasound surgery for use in fetal medicine
    I H Rivens
    Joint Department of Physics, The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Ultrasound 9:89-97. 1999
    ..In the work described in this paper, the application of FUS is extended to investigate the potential to induce vascular occlusion, with the aim of applying the technique to problems in fetal medicine and oncology...
  68. ncbi An algorithm for the optimum combination of data from arbitrary magnetic resonance phased array probes
    T Prock
    CRC Clinical MR Research Group, The Institute of Cancer Research, Royal Marsden NHS Trust, Sutton, Surrey, UK
    Phys Med Biol 47:N39-46. 2002
    ..5 T (Dzik-Jurasz A S K, Murphy P S, George M, Prock T, Collins D J, Swift I and Leach M O 2001 Magn. Reson. Med. at press), showing improvements of combined spectral SNR of up to 34% over the maximum SNR from a single element...
  69. ncbi Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics
    G J Parker
    Cancer Research Campaign Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    J Magn Reson Imaging 7:564-74. 1997
    ..Quantification of permeability and leakage space provides a method for comparing physiology in patients between visits or for intersite comparisons...
  70. ncbi Introduction to in vivo MRS of cancer: new perspectives and open problems
    M O Leach
    CRC Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Anticancer Res 16:1503-14. 1996
    ..In this paper, recent reports of NMR spectroscopy in cancer are reviewed, together with the requirements for tumour measurements...
  71. ncbi Sliding window dual gradient echo (SW-dGRE): T1 and proton resonance frequency (PRF) calibration for temperature imaging in polyacrylamide gel
    J T Ong
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, Surrey, UK
    Phys Med Biol 48:1917-31. 2003
    ..The advantage of this sequence is that the temperature obtained from the magnitude data can be confirmed independently using the phase data and vice versa. Thus the sequence can essentially be crosschecked...
  72. ncbi Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment
    M O Leach
    CRC Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    NMR Biomed 11:314-40. 1998
    ....
  73. ncbi Evaluation of 31P high-resolution magic angle spinning of intact tissue samples
    G S Payne
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    NMR Biomed 19:593-8. 2006
    ....
  74. ncbi Proton spectroscopic imaging of polyacrylamide gel dosimeters for absolute radiation dosimetry
    P S Murphy
    Joint Department of Physics, The Institute of Cancer Research, The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Phys Med Biol 45:835-45. 2000
    ....
  75. ncbi Initial measurements of ifosfamide and cyclophosphamide in patients using (31)P MRS: pulse-and-acquire, decoupling, and polarization transfer
    G S Payne
    CRC Clinical Magnetic Resonance Research Group, NHS Trust, Downs Road, Sutton, Surrey, UK
    Magn Reson Med 44:180-4. 2000
    ..Factors affecting signal enhancement in vivo are evaluated. Magn Reson Med 44:180-184, 2000...
  76. ncbi The use of gel dosimetry for verification of electron and photon treatment plans in carcinoma of the scalp
    J V Trapp
    Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Phys Med Biol 49:1625-35. 2004
    ....
  77. ncbi Consecutive projections onto convex sets
    A Degenhard
    CRC Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Phys Med Biol 47:N61-6. 2002
    ..The proposed method is of value for many finite sampling imaging problems including, in particular, fast-scan magnetic resonance imaging applications...
  78. ncbi Dose resolution in gel dosimetry: effect of uncertainty in the calibration function
    J V Trapp
    Joint Department of Physics, The Institute of Cancer Research, Royal Marsden Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Phys Med Biol 49:N139-46. 2004
    ..In this note we examine how the goodness of fit of the calibration function affects DdeltaP and show that its inclusion in the calculation of DdeltaP is essential to avoid overestimating the performance of the gel...
  79. ncbi The reproducibility of polyacrylamide gel dosimetry applied to stereotactic conformal radiotherapy
    V P Cosgrove
    Joint Department of Physics, The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Phys Med Biol 45:1195-210. 2000
    ....
  80. ncbi Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging
    Carmel Hayes
    CRC Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Downs Road, Sutton SM2 5PT, UK
    NMR Biomed 15:154-63. 2002
    ..Thus, for higher pre-treatment K(trans) values, a greater decrease was observed. Greater changes were observed in the upper extremes of the K(trans) histogram than in the median values after one course of treatment...
  81. ncbi Computerized detection of breast lesions in multi-centre and multi-instrument DCE-MR data using 3D principal component maps and template matching
    Gokhan Ertas
    Cancer Research UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Phys Med Biol 56:7795-811. 2011
    ..02/lesion, 1.17/case and 0.08/slice, comparing favourably with previous studies. This approach may facilitate detection of lesions in multi-centre and multi-instrument dynamic contrast-enhanced breast MR data...
  82. ncbi Human gallbladder bile: noninvasive investigation in vivo with single-voxel 1H MR spectroscopy
    Andrew P Prescot
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Surrey, England, UK
    Radiology 229:587-92. 2003
    ..8) were within the expected range of levels in human bile. Findings in this preliminary investigation indicate that human gallbladder bile can be qualitatively and quantitatively studied noninvasively with 1H MR spectroscopy...
  83. ncbi Measurements of occupational exposure to switched gradient and spatially-varying magnetic fields in areas adjacent to 1.5 T clinical MRI systems
    Sophie F Riches
    Cancer Research UK Clinical Magnetic Resonance Research Group, Royal Marsden NHS Trust and Institute of Cancer Research, Surrey, UK
    J Magn Reson Imaging 26:1346-52. 2007
    ..5 T magnetic resonance imaging (MRI) scanners during image acquisition and when moving in the spatially-varying static magnetic field is compliant with European Union (EU) Directive 2004/40/EC (the Directive)...
  84. ncbi Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies
    Timothy A Yap
    Royal Marsden National Health Service Foundation Trust, The Institute of Cancer Research, Sutton, Surrey, UK
    J Clin Oncol 29:1271-9. 2011
    ..A phase I trial of ARQ 197 was conducted to assess safety, tolerability, and target inhibition, including intratumoral c-MET signaling, apoptosis, and angiogenesis...
  85. ncbi Modulating the relaxivity of hyperpolarized substrates with gadolinium contrast agents
    Cristina Gabellieri
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK
    Contrast Media Mol Imaging 4:143-7. 2009
    ....
  86. ncbi Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis
    S M Ronen
    Cancer Research Campaign, Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 80:1035-41. 1999
    ..The 31P MR spectrum of tumours responding to chemotherapy could be modulated by similar effects...
  87. ncbi Dynamic contrast-enhanced MRI for prostate cancer localization
    A S N Jackson
    Academic Department of Radiotherapy and Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK
    Br J Radiol 82:148-56. 2009
    ..006) and similarly specific (85% vs 81%; p = 0.593). The superior sensitivity of DCE-MRI compared with T2W images, together with its high specificity, is arguably sufficient for its use in guiding radiotherapy boosts in prostate cancer...
  88. ncbi 1H decoupling for in vivo (19)F MRS studies using the time-share modulation method on a clinical 1.5 T NMR system
    B S Li
    CRC Clinical Magnetic Resonance Research Group, Institute of Cancer Research and the Royal Marsden NHS Trust, Surrey, UK
    Magn Reson Med 44:5-9. 2000
    ..This method has been demonstrated in vivo in patients receiving 5-fluorouracil chemotherapy. Magn Reson Med 44:5-9, 2000...
  89. ncbi A comparison of in vivo and in vitro 31P NMR spectra from human breast tumours: variations in phospholipid metabolism
    T A Smith
    Department of Nuclear Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 63:514-6. 1991
    ..We believe this to be a consequence of phospholipid, which would not appear in the aqueous extract, contributing to the phosphodiester peak in vivo...
  90. ncbi The effects of paramagnetic contrast agents on metabolite protons in aqueous solution
    Philip S Murphy
    CRC Clinical MR Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Phys Med Biol 47:N53-9. 2002
    ..The maximum potential influence of the contrast agents on in vivo metabolite signals was calculated using the measured relaxivities...
  91. ncbi Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single- and double-resonance 31P MRS
    Laura Mancini
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden NHS Trust, Sutton, UK
    Magn Reson Med 50:249-55. 2003
    ..Other peaks observed in bile are tentatively assigned to carboxy-ifosfamide and dechloroethyl-ifosfamide. Overall, (1)H-decoupled (31)P MRS has proved to be a useful tool for investigating the metabolism of ifosfamide in vivo...
  92. ncbi Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients
    Dow Mu Koh
    Academic Department of Radiology, Royal Marsden Hospital, Downs Rd, Sutton, Surrey, United Kingdom, SM2 5PT
    AJR Am J Roentgenol 188:1001-8. 2007
    ....
  93. ncbi Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer
    S J Vaidya
    Department of Paediatric Oncology, Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, Surrey, UK
    Eur J Cancer 39:728-35. 2003
    ..This review suggests that several markers and ratios are emerging as potential prognostic markers, but larger prospective studies are needed before translating this into clinical practice...
  94. ncbi Reproducibility of quantitative dynamic MRI of normal human tissues
    Anwar R Padhani
    CRC Clinical Magnetic Resonance Research Group, Institute of Cancer Research and the Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    NMR Biomed 15:143-53. 2002
    ..Reproducibility studies of normal and pathological tissues should be incorporated into clinical research protocols that measure treatment effects by DCE-MRI techniques...
  95. ncbi Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging alone
    Young K Lee
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Radiother Oncol 66:203-16. 2003
    ..MR treatment planning was demonstrated using a large bandwidth sequence and bulk-assigned images. The development of higher quality, low distortion MR sequence will allow regular practice of this technique...
  96. ncbi Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
    P S Murphy
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 90:781-6. 2004
    ..035) and 3-month scan (P=0.021). The reduction in the tumour choline/water signal paralleled tumour volume change and may reflect the therapeutic effect of temozolomide...
  97. ncbi The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate
    T A Smith
    Department of Nuclear Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 64:821-6. 1991
    ..The concentration of phosphoethanolamine did not correlate with either of these measures of proliferation rate. The concentration of glycerophosphorylethanolamine showed a weak negative correlation with the number of cells in S-phase...
  98. ncbi Measurement of the three-dimensional distribution of radiation dose in grid therapy
    J V Trapp
    Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Phys Med Biol 49:N317-23. 2004
    ..It is shown that the radiation dose is attenuated more rapidly with depth in a grid field than an open field, and that even shielded regions receive approximately 25% of the dose to the unshielded areas...
  99. ncbi Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI
    M J White
    Cancer Research UK Clinical Magnetic Resonance Research Group, Royal Marsden NHS Trust and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Radiol 80:113-20. 2007
    ..This method for MR voxel-based parametric mapping of HPI has the potential to demonstrate regional variations in perfusion at the segmental and subsegmental level...
  100. ncbi A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer
    J L Mansi
    Breast Unit, Royal Marsden Hospital, Sutton, Surrey
    Br J Cancer 64:593-7. 1991
    ..Lonidamine appears to be active against advanced breast cancer and its low toxicity would allow combination studies with chemotherapy...
  101. ncbi Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Research
    M O Leach
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK
    Phys Med Biol 51:R61-82. 2006
    ..Applications using particular nuclei will then be described and related to other experimental work where appropriate. Contributions to the development of MRS that have been published in Physics in Medicine and Biology will be discussed...